Liang Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liang Huang has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Chi Zhang
Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, Hengyang Medical School, University of South China
8 shared publications Yi-Zhang Liu
Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, Hengyang Medical School, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, People’s Republic of China
6 shared publicationsMu-Yao Tang
Research Laboratory of Translational Medicine, Hengyang Medical School, University of South China
5 shared publicationsShun-Lin Qu
Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan province, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, PR China
5 shared publicationsXuan Xiao
Research Laboratory of Translational Medicine, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China; Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China; Departments of Clinical Medicine, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China
5 shared publicationsChi Zhang
Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan province, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, PR China
4 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1790479
Lactylation: a metabolic–epigenetic driver in atherosclerosis pathogenesis and therapeutic targeting
Atherosclerosis (AS), a disease of large and medium-sized arteries, is a common cause of cardiovascular morbidity and mortality. Lactylation is a recently identified post-translational modification involving the addition of lactate-derived lactyl groups to lysine residues on proteins. Studies suggest that lactylation plays a vital role in AS development by regulating several key pathological processes. These include inflammation, epithelial–mesenchymal transition, angiogenesis, vascular smooth muscle cell senescence and transdifferentiation, and metabolic dysregulation associated with atherosclerosis. This review summarizes the molecular mechanisms through which lactylation contributes to AS initiation and progression, providing a clearer understanding of the underlying pathophysiological processes. Further elucidation of lactylation may provide novel mechanistic insights into AS development and identify lactylation-targeted interventions as promising strategies to slow AS progression and reduce cardiovascular events.
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1790479
Open AccessLactylation: a metabolic–epigenetic driver in atherosclerosis pathogenesis and therapeutic targeting
Atherosclerosis (AS), a disease of large and medium-sized arteries, is a common cause of cardiovascular morbidity and mortality. Lactylation is a recently identified post-translational modification involving the addition of lactate-derived lactyl groups to lysine residues on proteins. Studies suggest that lactylation plays a vital role in AS development by regulating several key pathological processes. These include inflammation, epithelial–mesenchymal transition, angiogenesis, vascular smooth muscle cell senescence and transdifferentiation, and metabolic dysregulation associated with atherosclerosis. This review summarizes the molecular mechanisms through which lactylation contributes to AS initiation and progression, providing a clearer understanding of the underlying pathophysiological processes. Further elucidation of lactylation may provide novel mechanistic insights into AS development and identify lactylation-targeted interventions as promising strategies to slow AS progression and reduce cardiovascular events.
- 19 May 2026
- Published by Elsevier in The Journal of Nutrition
- Vol. 156 (7) , 101599
Taurine in Atherosclerosis: A Multitarget Perspective
- 19 May 2026
- Published by Elsevier in The Journal of Nutrition
- Vol. 156 (7) , 101599
Taurine in Atherosclerosis: A Multitarget Perspective
- 9 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 139, 156488
Innovative approaches in atherosclerosis treatment: Harnessing traditional Chinese medicine to target long non-coding RNAs
- 9 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 139, 156488
Innovative approaches in atherosclerosis treatment: Harnessing traditional Chinese medicine to target long non-coding RNAs
- 1 December 2024
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 102 (6) , 418-429
Pathophysiological relevance and therapeutic outlook of GPR43 in atherosclerosis
Atherosclerosis (AS) is an inflammatory arterial disorder that occurs due to the deposition of the excessive lipoprotein under the artery intima, mainly including low-density lipoprotein and other apolipoprotein B-containing lipoproteins. G protein-coupled receptors (GPCRs) play a crucial role in transmitting signals in physiological and pathophysiological conditions. GPCRs recognize inflammatory mediators, thereby serving as important players during chronic inflammatory processes. It has been demonstrated that free fatty acids can function as ligands for various GPCRs, such as free fatty acid receptor (FFAR)1/GPR40, FFAR2/GPR43, FFAR3/GPR41, FFAR4/GPR120, and the lipid metabolite binding glucose-dependent insulinotropic receptor (GPR119). This review discusses GPR43 and its ligands in the pathogenesis of AS, especially focusing on its distinct role in regulating chronic vascular inflammation, inhibiting oxidative stress, ameliorating endothelial dysfunction and improving dyslipidemia. It is hoped that this review may provide guidance for further studies aimed at GPR43 as a promising target for drug development in the prevention and therapy of AS.
- 1 December 2024
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 102 (6) , 418-429
Pathophysiological relevance and therapeutic outlook of GPR43 in atherosclerosis
Atherosclerosis (AS) is an inflammatory arterial disorder that occurs due to the deposition of the excessive lipoprotein under the artery intima, mainly including low-density lipoprotein and other apolipoprotein B-containing lipoproteins. G protein-coupled receptors (GPCRs) play a crucial role in transmitting signals in physiological and pathophysiological conditions. GPCRs recognize inflammatory mediators, thereby serving as important players during chronic inflammatory processes. It has been demonstrated that free fatty acids can function as ligands for various GPCRs, such as free fatty acid receptor (FFAR)1/GPR40, FFAR2/GPR43, FFAR3/GPR41, FFAR4/GPR120, and the lipid metabolite binding glucose-dependent insulinotropic receptor (GPR119). This review discusses GPR43 and its ligands in the pathogenesis of AS, especially focusing on its distinct role in regulating chronic vascular inflammation, inhibiting oxidative stress, ameliorating endothelial dysfunction and improving dyslipidemia. It is hoped that this review may provide guidance for further studies aimed at GPR43 as a promising target for drug development in the prevention and therapy of AS.
- 18 August 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (6) , e4107
Role of osteokines in atherosclerosis
Despite their diverse physiologies and roles, the heart, skeletal muscles, and smooth muscles all derive from a common embryonic source as bones. Moreover, bone tissue, skeletal and smooth muscles, and the heart share conserved signaling pathways. The maintenance of skeletal health is precisely regulated by osteocytes, osteoblasts, and osteoclasts through coordinated secretion of bone‐derived factors known as osteokines. Increasing evidence suggests the involvement of osteokines in regulating atherosclerotic vascular disease. Therefore, this review aims to examine the evidence for the role of osteokines in atherosclerosis development and progression comprehensively. Specifically discussed are extensively studied osteokines in atherosclerosis such as osteocalcin, osteopontin, osteoprotegerin, and fibroblast growth factor 23. Additionally, we highlighted the effects of exercise on modulating these key regulators derived from bone tissue metabolism. We believe that gaining an enhanced understanding of how osteocalcin contributes to the process of atherosclerosis will enable us to develop targeted and comprehensive therapeutic strategies against diseases associated with its progression.
- 18 August 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (6) , e4107
Role of osteokines in atherosclerosis
Despite their diverse physiologies and roles, the heart, skeletal muscles, and smooth muscles all derive from a common embryonic source as bones. Moreover, bone tissue, skeletal and smooth muscles, and the heart share conserved signaling pathways. The maintenance of skeletal health is precisely regulated by osteocytes, osteoblasts, and osteoclasts through coordinated secretion of bone‐derived factors known as osteokines. Increasing evidence suggests the involvement of osteokines in regulating atherosclerotic vascular disease. Therefore, this review aims to examine the evidence for the role of osteokines in atherosclerosis development and progression comprehensively. Specifically discussed are extensively studied osteokines in atherosclerosis such as osteocalcin, osteopontin, osteoprotegerin, and fibroblast growth factor 23. Additionally, we highlighted the effects of exercise on modulating these key regulators derived from bone tissue metabolism. We believe that gaining an enhanced understanding of how osteocalcin contributes to the process of atherosclerosis will enable us to develop targeted and comprehensive therapeutic strategies against diseases associated with its progression.
- 5 July 2023
- Published by Elsevier in Toxicology Letters
- Vol. 383, 204-212
Indoxyl sulfate in atherosclerosis
- 5 July 2023
- Published by Elsevier in Toxicology Letters
- Vol. 383, 204-212
Indoxyl sulfate in atherosclerosis
- 13 June 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (5) , 1079-1092
IRE1α: from the function to the potential therapeutic target in atherosclerosis
Inositol requiring enzyme 1 (IRE1) is generally thought to control the most conserved pathway in the unfolded protein response (UPR). Two isoforms of IRE1, IRE1α and IRE1β, have been reported in mammals. IRE1α is a ubiquitously expressed protein whose knockout shows marked lethality. In contrast, the expression of IRE1β is exclusively restricted in the epithelial cells of the respiratory and gastrointestinal tracts, and IRE1β-knockout mice are phenotypically normal. As research continues to deepen, IRE1α was showed to be tightly linked to inflammation, lipid metabolism regulation, cell death and so on. Growing evidence also suggests an important role for IRE1α in promoting atherosclerosis (AS) progression and acute cardiovascular events through disrupting lipid metabolism balance, facilitating cells apoptosis, accelerating inflammatory responses and promoting foam cell formation. In addition, IRE1α was recognized as novel potential therapeutic target in AS prevention. This review provides some clues about the relationship between IRE1α and AS, hoping to contribute to further understanding roles of IRE1α in atherogenesis and to be helpful for the design of novel efficacious therapeutics agents targeting IRE1α-related pathways.
- 13 June 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (5) , 1079-1092
IRE1α: from the function to the potential therapeutic target in atherosclerosis
Inositol requiring enzyme 1 (IRE1) is generally thought to control the most conserved pathway in the unfolded protein response (UPR). Two isoforms of IRE1, IRE1α and IRE1β, have been reported in mammals. IRE1α is a ubiquitously expressed protein whose knockout shows marked lethality. In contrast, the expression of IRE1β is exclusively restricted in the epithelial cells of the respiratory and gastrointestinal tracts, and IRE1β-knockout mice are phenotypically normal. As research continues to deepen, IRE1α was showed to be tightly linked to inflammation, lipid metabolism regulation, cell death and so on. Growing evidence also suggests an important role for IRE1α in promoting atherosclerosis (AS) progression and acute cardiovascular events through disrupting lipid metabolism balance, facilitating cells apoptosis, accelerating inflammatory responses and promoting foam cell formation. In addition, IRE1α was recognized as novel potential therapeutic target in AS prevention. This review provides some clues about the relationship between IRE1α and AS, hoping to contribute to further understanding roles of IRE1α in atherogenesis and to be helpful for the design of novel efficacious therapeutics agents targeting IRE1α-related pathways.
- 17 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (10) , 9893-9902
Role of Sp1 in atherosclerosis
Specificity protein (Sp) is a famous family of transcription factors including Sp1, Sp2 and Sp3. Sp1 is the first one of Sp family proteins to be characterized and cloned in mammalian. It has been proposed that Sp1 acts as a modulator of the expression of target gene through interacting with a series of proteins, especially with transcriptional factors, and thereby contributes to the regulation of diverse biological processes. Notably, growing evidence indicates that Sp1 is involved in the main events in the development of atherosclerosis (AS), such as inflammation, lipid metabolism, plaque stability, vascular smooth muscle cells (VSMCs) proliferation and endothelial dysfunction. This review is designed to provide useful clues to further understanding roles of Sp1 in the pathogenesis of AS, and may be helpful for the design of novel efficacious therapeutics agents targeting Sp1.
- 17 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (10) , 9893-9902
Role of Sp1 in atherosclerosis
Specificity protein (Sp) is a famous family of transcription factors including Sp1, Sp2 and Sp3. Sp1 is the first one of Sp family proteins to be characterized and cloned in mammalian. It has been proposed that Sp1 acts as a modulator of the expression of target gene through interacting with a series of proteins, especially with transcriptional factors, and thereby contributes to the regulation of diverse biological processes. Notably, growing evidence indicates that Sp1 is involved in the main events in the development of atherosclerosis (AS), such as inflammation, lipid metabolism, plaque stability, vascular smooth muscle cells (VSMCs) proliferation and endothelial dysfunction. This review is designed to provide useful clues to further understanding roles of Sp1 in the pathogenesis of AS, and may be helpful for the design of novel efficacious therapeutics agents targeting Sp1.
- 1 October 2021
- Published by Elsevier in Clinica Chimica Acta
- Vol. 521, 19-24
Angiopoietin-like proteins in atherosclerosis
- 1 October 2021
- Published by Elsevier in Clinica Chimica Acta
- Vol. 521, 19-24
Angiopoietin-like proteins in atherosclerosis